Coherus BioSciences has agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial (HKF) for up-front all-cash consideration of $40 million.
YUSIMRY is a multi-indication biosimilar to AbbVie’s HUMIRA (adalimumab). YUSIMRY is indicated for use across multiple rheumatologic, gastroenterologic, and dermatologic indications, including: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa.
Meitheal Pharmaceuticals, a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the U.S.
“With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “The proceeds from the sale of YUSIMRY will bolster our cash position, advance our efforts to become a sustainable and growing oncology company and efficiently allocate our resources for maximum value creation.”
Coherus’ oncology assets include LOQTORZI (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor, the UDENYCA (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; and an innovative clinical-stage, immuno-oncology portfolio focused on the tumor microenvironment.
